• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pathogenetic factors underlying juvenile deep vein thrombosis (DVT) in Indians.

作者信息

Saxena R, Mohanty S, Srivastava A, Choudhry V P, Kotwal J

机构信息

Department of Haematology, All India Institute of Medical Sciences, New Delhi.

出版信息

Eur J Haematol. 1999 Jul;63(1):26-8. doi: 10.1111/j.1600-0609.1999.tb01846.x.

DOI:10.1111/j.1600-0609.1999.tb01846.x
PMID:10414451
Abstract

The role of hereditary antithrombotic protein defects in juvenile deep vein thrombosis (DVT) was evaluated. Fifty six young patients (age <45 yr) with doppler-proven DVT were investigated for the presence of resistance to activated protein C (APC-R), lupus anticoagulant (LA), anticardiolipin antibodies and deficiencies of protein C, protein S, ATIII activities. Fifty nine normal healthy individuals served as controls. APC-R was observed to be the commonest defect underlying the Indian DVT as seen in 39.2% of patients followed by elevated ACA (5.3%), PAI (2.8%), presence of LA (2.8%) and reduced ATIII levels (2.8%). None of the subjects had protein C or S deficiency. APC-R was associated with ATIII deficiency in one case, and elevated ACA in two cases. In two subjects, APC-R was associated with elevated PAI levels. Patients with more than one prothrombotic factor had a higher prevalence of pulmonary thromboembolism, suggesting that the thrombogenic potential of APC-R is enhanced by the presence of coexisting hereditary or acquired prothrombotic defect.

摘要

相似文献

1
Pathogenetic factors underlying juvenile deep vein thrombosis (DVT) in Indians.
Eur J Haematol. 1999 Jul;63(1):26-8. doi: 10.1111/j.1600-0609.1999.tb01846.x.
2
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].[深静脉血栓形成患者的活化蛋白C抵抗、莱顿突变、抗凝蛋白及纤维蛋白原水平]
Pol Arch Med Wewn. 2003 Jun;109(6):579-88.
3
Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis.纤溶酶原激活物抑制剂-1(PAI-1)基因 4G/5G 启动子多态性在印度深静脉血栓形成患者中更为常见。
Clin Appl Thromb Hemost. 2010 Apr;16(2):184-8. doi: 10.1177/1076029609333673. Epub 2009 May 5.
4
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Thromb Haemost. 2002 Nov;88(5):716-22.
5
Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.上肢原发性深静脉血栓形成的危险因素及复发率
Circulation. 2004 Aug 3;110(5):566-70. doi: 10.1161/01.CIR.0000137123.55051.9B. Epub 2004 Jul 19.
6
Venous thrombosis: prevalence of prothrombotic defects in north Indian population.静脉血栓形成:印度北部人群中血栓前状态缺陷的患病率
Indian J Pathol Microbiol. 2003 Oct;46(4):621-4.
7
Frequency of prothrombotic risk factors in patients with deep venous thrombosis and controls: their implications for thrombophilia screening in Chilean subjects.深静脉血栓形成患者与对照组中血栓前危险因素的频率:其对智利人群血栓形成倾向筛查的意义。
Genet Test Mol Biomarkers. 2010 Oct;14(5):599-602. doi: 10.1089/gtmb.2010.0012. Epub 2010 Aug 14.
8
[Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis].121例静脉或动脉血栓形成患者的抗凝血酶III、蛋白C、蛋白S和因子XII遗传性缺乏症
Srp Arh Celok Lek. 1999 Jan-Feb;127(1-2):21-7.
9
[A study on the deficiency of anticoagulant proteins in Chinese patients with deep venous thrombosis].[中国深静脉血栓形成患者抗凝蛋白缺乏的研究]
Zhonghua Nei Ke Za Zhi. 2000 Nov;39(11):746-8.
10
Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects.原发性上肢深静脉血栓形成:血栓形成倾向缺陷的高患病率。
Am J Hematol. 2004 Aug;76(4):330-7. doi: 10.1002/ajh.20131.

引用本文的文献

1
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.比较培非替尼 25、50、100 和 150mg 在活动性类风湿关节炎患者中的疗效和安全性:一项基于随机对照试验的贝叶斯网络荟萃分析。
Clin Drug Investig. 2020 Jan;40(1):65-72. doi: 10.1007/s40261-019-00863-9.
2
Clinical profile, common thrombophilia markers and risk factors in 85 young Indian patients with arterial thrombosis.85例年轻印度动脉血栓形成患者的临床特征、常见血栓形成倾向标志物及危险因素
Sao Paulo Med J. 2013;131(6):384-8. doi: 10.1590/1516-3180.2013.1316369.
3
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
印度原发性静脉血栓形成患者常见血栓形成倾向标志物及危险因素的患病率
Sao Paulo Med J. 2010;128(5):263-7. doi: 10.1590/s1516-31802010000500004.